PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sodium aurothiomalate - Rheumatoid arthritis
PAD Profile : Sodium aurothiomalate - Rheumatoid arthritis Important
Keywords :
GOLD, RA
Brand Names Include :
Myocrisin
Important Information :
Severe disease only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Abatacept
- Certolizumab pegol
- Etanercept
- Golimumab
- Penicillamine
- Rituximab
- Tocilizumab
- Adalimumab
- Infliximab
- Baricitinib
- Tofacitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network considers the prescribing of sodium aurothiomalate in rheumatoid arthritis in NEW patients to be RED - specialist ONLY drugs - treatment initiated and continued by specialist clinicians.
Please note:
- For any new patients initiated on sodium aurothiomalate, prescribing should be retained by the specialist.
- For any patients currently taking sodium aurothiomalate in primary care, monitoring should be retained in primary care and requirements should be as described in the current BNF and SPC.
Primary care monitoring requirements for people on sodium aurothiomalate are available from CKS at: https://cks.nice.org.uk/dmards#!scenario:7
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs